Modelling the metabolic consequences of antimicrobial exposure

Abstract

Besides genetic mutations, the metabolic state of bacterial cells represents another driving factor in the emergence of antimicrobial resistance and in the actual efficacy of treatments. In this direction, studying how bacteria reprogram their metabolism when facing antimicrobial exposure is crucial to enhance our ability to limit the development and spread of antibiotic resistance. Here we have studied the metabolic consequences of antimicrobial exposure in bacteria using an integrated approach that exploits transcriptomics and computational modelling. Specifically, we asked whether common metabolic strategies emerge during the exposure to antimicrobials, regardless of the kind of antimicrobial used or, on the contrary, antimicrobial-specific pathways exist. To this purpose, we have used an heterogeneous dataset from six published studies on Escherichia coli exposed to different concentrations/types of compounds. We show that experimental condition, not antimicrobial exposure, is the factor that influences the most the resulting metabolic networks. However, despite condition-dependent metabolic signatures being evident, specific changes in flux distributions by antimicrobial exposed cells could be identified. In particular, purine and pyrimidine biosynthesis, and cofactor and prosthetic group biosynthesis were commonly affected by all considered antimicrobials. This suggests the presence of general metabolic strategies to face the stress posed by antimicrobial exposure and that, in turn, may represent an untapped resource for the fight against microbial infections. Finally, our analysis predicted an overall metabolic rewiring following bacteriostatic vs. bactericidal drug exposure that is in line with the current knowledge about the effects of these two classes of compounds on microbial metabolic phenotypes. IMPORTANCEA mechanistic understanding of microbial metabolic reprogramming during antimicrobial exposure is key to facilitate the discovery of new resistance mechanisms and to identify novel areas of intervention to face microbial infections. This study shows how the integration of transcriptomic data and genome-scale metabolic modelling can be used to address this critical issue, and to trace general metabolic strategies exploited by bacteria to face the stress posed by antimicrobial drugs.